East Asia & Pacific (IDA & IBRD countries) vs France: Immunization, Hib3
Immunization, Hib3 over time
- East Asia & Pacific (IDA & IBRD countries)
- France
How they compare
France currently reports 96.0% against 40.1% in East Asia & Pacific (IDA & IBRD countries), a difference of 55.9%.
That makes France's figure about 2.4 times East Asia & Pacific (IDA & IBRD countries)'s.
Across all 27 years both countries report, France has been ahead every year.
East Asia & Pacific (IDA & IBRD countries) ranks 43rd and France ranks 46th of 43 groups.
France has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | East Asia & Pacific (IDA & IBRD countries) | France | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.1% | 82.0% | 81.9% | France |
| 2000s | 1.2% | 92.8% | 91.6% | France |
| 2010s | 23.0% | 94.9% | 71.9% | France |
| 2020s | 36.7% | 96.0% | 59.3% | France |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, East Asia & Pacific (IDA & IBRD countries) or France?
- France, at 96.0% against 40.1% in East Asia & Pacific (IDA & IBRD countries) as of 2024.
- What is the difference in immunization, hib3 between East Asia & Pacific (IDA & IBRD countries) and France?
- 55.9%, with France ahead.
- How many years of comparable data are there for East Asia & Pacific (IDA & IBRD countries) and France?
- 27 years are reported by both, from 1998 to 2024.
- How do East Asia & Pacific (IDA & IBRD countries) and France rank globally for immunization, hib3?
- East Asia & Pacific (IDA & IBRD countries) ranks 43rd and France ranks 46th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.